United Laboratories International (HKG:3933) said China's National Medical Products Administration approved a new specification of its sodium hyaluronate eye drops, according to a Tuesday filing with the Hong Kong bourse.
The approval covers a 0.3% multi-dose formulation for treating corneal and conjunctival epithelial damage associated with dry eye syndrome and other eye conditions.
Shares of the bulk medicine company were up over 1% in afternoon trade on Wednesday.